Abbott Laboratories $ABT Shares Acquired by Tudor Financial Inc.

Tudor Financial Inc. boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 839.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,042 shares of the healthcare product maker’s stock after purchasing an additional 23,270 shares during the period. Abbott Laboratories comprises approximately 1.1% of Tudor Financial Inc.’s investment portfolio, making the stock its 27th biggest holding. Tudor Financial Inc.’s holdings in Abbott Laboratories were worth $2,363,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ABT. NWF Advisory Services Inc. grew its position in Abbott Laboratories by 6.4% during the second quarter. NWF Advisory Services Inc. now owns 11,419 shares of the healthcare product maker’s stock valued at $1,036,000 after buying an additional 686 shares during the period. NEOS Investment Management LLC raised its position in shares of Abbott Laboratories by 13.6% in the second quarter. NEOS Investment Management LLC now owns 284,296 shares of the healthcare product maker’s stock valued at $25,797,000 after buying an additional 33,962 shares during the last quarter. AXQ Capital LP raised its holdings in Abbott Laboratories by 905.1% in the 2nd quarter. AXQ Capital LP now owns 40,657 shares of the healthcare product maker’s stock valued at $3,689,000 after acquiring an additional 36,612 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Abbott Laboratories during the second quarter worth approximately $1,343,000. Finally, Mayport LLC raised its holdings in shares of Abbott Laboratories by 6.9% during the 2nd quarter. Mayport LLC now owns 4,090 shares of the healthcare product maker’s stock worth $371,000 after acquiring an additional 263 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Citigroup raised their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. TD Cowen increased their target price on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Finally, Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $108.29 on Monday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a fifty day moving average price of $104.43 and a 200 day moving average price of $100.03. The company has a market cap of $187.38 billion, a PE ratio of 35.05, a P/E/G ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the prior year, the company posted $1.26 earnings per share. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.